Surmodics ROA 2006-2018 | SRDX

Current and historical return on assets (ROA) values for Surmodics (SRDX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Surmodics ROA for the three months ending June 30, 2018 was 5.63%.
Surmodics Annual ROA
2017 2.87
2016 7.51
2015 12.10
2014 11.64
2013 14.30
2012 9.71
2011 6.97
2010 0.24
2009 20.24
2008 7.72
2007 1.95
2006 12.92
2005 -6.64
Surmodics Quarterly ROA
Q3 2018 -1.68
Q2 2018 0.94
Q1 2017 -1.16
Q4 2017 0.29
Q3 2017 0.55
Q2 2017 0.39
Q1 2016 1.79
Q4 2016 1.94
Q3 2016 3.10
Q2 2016 0.67
Q1 2015 2.36
Q4 2015 1.38
Q3 2015 4.09
Q2 2015 3.36
Q1 2014 4.15
Q4 2014 2.33
Q3 2014 3.65
Q2 2014 2.57
Q1 2013 3.82
Q4 2013 3.66
Q3 2013 3.06
Q2 2013 3.18
Q1 2012 3.94
Q4 2012 2.74
Q3 2012 2.01
Q2 2012 1.26
Q1 2011 1.42
Q4 2011 1.40
Q3 2011 1.76
Q2 2011 1.65
Q1 2010 1.66
Q4 2010 -12.72
Q3 2010 -0.48
Q2 2010 -0.22
Q1 2009 1.01
Q4 2009 1.46
Q3 2009 1.95
Q2 2009 2.32
Q1 2008 15.01
Q4 2008 -0.43
Q3 2008 2.46
Q2 2008 2.76
Q1 2007 3.25
Q4 2007 -8.12
Q3 2007 3.39
Q2 2007 4.11
Q1 2006 3.95
Q4 2006 4.00
Q3 2006 4.40
Q2 2006 1.08
Q1 2005 4.76
Q4 2005 3.86
Q3 2005 5.17
Q2 2005 -22.26
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.972B $0.073B
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $132.148B 20.26
Abbott Laboratories (ABT) United States $121.136B 25.39
Stryker (SYK) United States $65.261B 25.22
Boston Scientific (BSX) United States $52.233B 27.17
Baxter (BAX) United States $41.336B 28.13
Zimmer Biomet Holdings (ZBH) United States $26.744B 17.18
ResMed (RMD) United States $16.242B 32.25
Smith & Nephew SNATS (SNN) United Kingdom $16.130B 0.00
Canopy Growth (CGC) Canada $11.376B 0.00
Perrigo (PRGO) Ireland $10.065B 14.28
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.065B 20.57
Insulet (PODD) United States $6.029B 0.00
Haemonetics (HAE) United States $5.767B 52.63
ICU Medical (ICUI) United States $5.434B 36.82
Neogen (NEOG) United States $4.634B 73.73
GW Pharmaceuticals (GWPH) United Kingdom $4.581B 0.00
Agios Pharmaceuticals (AGIO) United States $4.266B 0.00
Hutchison China MediTech (HCM) China $3.798B 0.00
NuVasive (NUVA) United States $3.542B 33.60
National Vision Holdings (EYE) United States $3.271B 72.23
Quidel (QDEL) United States $2.532B 51.87
NxStage Medical (NXTM) United States $1.847B 0.00
Phibro Animal Health (PAHC) United States $1.708B 24.31
AtriCure (ATRC) United States $1.247B 0.00
Cardiovascular Systems (CSII) United States $1.233B 735.80
Omeros (OMER) United States $1.216B 0.00
VAREX IMAGING (VREX) United States $1.138B 18.60
Owens & Minor (OMI) United States $1.069B 11.44
PetIQ (PETQ) United States $1.069B 34.97
Eagle Pharmaceuticals (EGRX) United States $1.015B 29.95
Cerus (CERS) United States $0.985B 0.00
MacroGenics (MGNX) United States $0.938B 0.00
OraSure Technologies (OSUR) United States $0.938B 61.32
TG Therapeutics (TGTX) United States $0.745B 0.00
Insys Therapeutics (INSY) United States $0.679B 0.00
LeMaitre Vascular (LMAT) United States $0.667B 32.00
Meridian Bioscience (VIVO) United States $0.642B 21.96
Lantheus Holdings (LNTH) United States $0.599B 18.63
Evolus (EOLS) United States $0.502B 0.00
NanoString Technologies (NSTG) United States $0.499B 0.00
Quanterix (QTRX) United States $0.427B 0.00
Cytosorbents (CTSO) United States $0.423B 0.00
Utah Medical Products (UTMD) United States $0.357B 22.97
Surface Oncology (SURF) United States $0.332B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Bovie Medical (BVX) United States $0.243B 0.00
Rockwell Medical (RMTI) United States $0.228B 0.00
Chimerix (CMRX) United States $0.191B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.172B 0.00
Fonar (FONR) United States $0.155B 7.73
Chembio Diagnostics (CEMI) United States $0.135B 0.00
Female Health (VERU) United States $0.099B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.085B 0.00
Trinity Biotech (TRIB) Ireland $0.082B 24.50
United-Guardian (UG) United States $0.076B 16.62
InfuSystems Holdings (INFU) United States $0.066B 0.00
Neurotrope (NTRP) United States $0.066B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.049B 0.00
Capricor Therapeutics (CAPR) United States $0.033B 0.00
Myomo (MYO) United States $0.026B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Akers Biosciences Inc (AKER) United States $0.024B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00